Phase III randomized clinical trials16,17 have shown further improvement in the response rate and PFS when PD1 inhibitors were added to gemcitabine and cisplatin vs gemcitabine and cisplatin for first-line recurrent or metastatic NPC. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.